目的　探讨生长抑素 (sst)在乳腺癌中诊断和治疗的价值。方法　应用免疫组织化学方法对 30例原发性乳腺癌患者行sst和ERPR的表达。结果　有同侧腋窝淋巴结转移患者 11例 ,其中 8例sst(+ ) ;无同侧腋窝淋巴结转移者 19例 ,其中 7例sst(+ ) ,两组差异有显著性 (χ2 =3 .6 ,P <0 .0 5 )。良性乳腺瘤 10例 ;其中 4例sst(+ )与 2 0例乳腺癌sst(+ )相比 ,两组差异有非常显著性 (χ2 =9.2 2 ,P <0 .0 1)。结论　sst对原发性乳腺癌诊断及治疗有一定的潜力 Objective To investigate the value of somatostatin (sst) in the diagnosis and treatment of breast cancer. Methods The expression of sst and ERPR was performed in 30 patients with primary breast cancer by immunohistochemistry. Results There were 11 patients with ipsilateral axillary lymph node metastases, including 8 cases of sst(+); 19 cases without ipsilateral axillary lymph node metastases, of which 7 cases were sst(+), and the difference between the two groups was significant (χ2=3.6). P < 0 .0 5 ). Benign breast tumors in 10 cases; 4 cases of sst (+) compared with 20 cases of breast cancer sst (+), the difference between the two groups was very significant (χ2 =9.22, P <0. 01). Conclusion sst has certain potential for the diagnosis and treatment of primary breast cancer